Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).
Warde, P. et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 378, 2104–2111 (2011).
Widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373, 301–308 (2009).
Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).
Pu, Y. et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci. Transl. Med. 8, 333ra47–333ra47 (2016).
Radojević, K. et al. Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level. J. Endocrinol. 192, 669–682 (2007).
Sutherland, J. S. et al. Activation of thymic regeneration in mice and humans following androgen blockade. J. Immunol. 175, 2741–2753 (2005).
Drake, C. G. et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7, 239–249 (2005).
Gannon, P. O. et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 348, 9–17 (2009).
Atala, A. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302 (2010).
Hölzel, M., Bovier, A. & Tüting, T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat. Rev. Cancer 13, 365–376 (2013).
Kanno, Y., Vahedi, G., Hirahara, K., Singleton, K. & O’Shea, J. J. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu Rev. Immunol. 30, 707–731 (2012).
Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51 (2010).
DuPage, M. & Bluestone, J. A. Harnessing the plasticity of CD4 + T cells to treat immune-mediated disease. Nat. Rev. Immunol. 16, 149–163 (2016).
Wang, Y.-H. et al. A novel subset of CD4 + TH2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J. Exp. Med 207, 2479–2491 (2010).
Dominguez-Villar, M., Baecher-Allan, C. M. & Hafler, D. A. Identification of T helper type 1–like, Foxp3 + regulatory T cells in human autoimmune disease. Nat. Med 17, 673–675 (2011).
Koenen, H. J. P. M. et al. Human CD25 high Foxp3 pos regulatory T cells differentiate into IL-17 – producing cells. Blood 112, 2340–2352 (2008).
Bending, D. et al. Highly purified Th17 cells from BDC2. 5NOD mice convert into Th1-like cells in NOD / SCID recipient mice. J. Clin. Invest 119, 565–572 (2009).
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R. & Weaver, C. T. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc. Natl. Acad. Sci. 112, 7061–7066 (2015).
Naji, A. et al. CD3 + CD4 low and CD3 + CD8 low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 110, 3936–3948 (2007).
Dianzani, U. et al. Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype. Blood 83, 2198–2205 (1994).
Pesenti, E. et al. Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5-dependent HIV type 1 isolates. AIDS Res Hum. Retrovir. 15, 983–987 (1999).
Greenberg, N. M. et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 92, 3439–3443 (1995).
Gingrich, J. R. et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57, 4687–4691 (1997).
Comiskey, M. et al. Evidence that HLA-G is the functional homolog of mouse Qa-2, the ped gene product. Hum. Immunol. 64, 999–1004 (2003).
Zhang, Q. et al. CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer. Cancer Res 75, 4312–4321 (2015).
DeNardo, D. G. et al. CD4 + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing Protumor Properties of Macrophages. Cancer Cell 16, 91–102 (2009).
Gomes, A. L. et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30, 161–175 (2016).
Chung, A. S. et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med 19, 1114–1123 (2013).
Chang, S. H. et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 111, 5664–5669 (2014).
Zanganeh, S. et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11, 986–994 (2016).
Tymoszuk, P. et al. In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur. J. Immunol. 44, 2247–2262 (2014).
Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. & Greenberg, N. M. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57, 3325–3330 (1997).
Savino, W., Mendes-da-Cruz, D. A., Lepletier, A. & Dardenne, M. Hormonal control of T-cell development in health and disease. Nat. Rev. Endocrinol. 12, 77–89 (2016).
Qu, P., Du, H., Wilkes, D. S. & Yan, C. Critical roles of lysosomal acid lipase in T cell development and function. Am. J. Pathol. 174, 944–956 (2009).
Almena, M., Andrada, E., Liebana, R. & Merida, I. Diacylglycerol metabolism attenuates T-cell receptor signaling and alters thymocyte differentiation. Cell Death Dis. 4, e912 (2013).
Monier, J. & Paradin, R. G. Effects of PGE2 upon differentiation and programmed cell death of suspension cultured CD4-CD8- thymocytes. Int. J. Immunopharmac. 16, 775 (1994).
Boniface, K. et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med 206, 535–548 (2009).
Basler, J. W. & Piazza, G. A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J. Urol. 171, S59–S62 (2004).
Drew, D. A., Cao, Y. & Chan, A. T. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat. Rev. Cancer 16, 173–186 (2016).
Roy, HK et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut 66, 285-292 (2017).
Cuzick, J. et al. Prevention and early detection of prostate cancer. Lancet Oncol. 15, e484–e492 (2014).
Burn, J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet 378, 2081–2087 (2011).
James, N. D. et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 13, 549–558 (2012).
Karan, D., Holzbeierlein, J. M., Van Veldhuizen, P. & Thrasher, J. B. Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat. Rev. Urol. 9, 376–385 (2012).
Nakanishi, M. & Rosenberg, D. W. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 35, 123–137 (2013).
Ventevogel, M. S. & Sempowski, G. D. Thymic rejuvenation and aging. Curr. Opin. Immunol. 25, 516–522 (2013).
Qian, X. et al. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J. Immunol. 190, 5894–5902 (2013).
Carothers, A. M., Moran, A. E., Cho, N. L., Redston, M. & Bertagnolli, M. M. Changes in antitumor response in C57BL/6J-Min/ + mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res 66, 6432–6438 (2006).
Karantanos, T. et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 67, 470–479 (2015).
Shen, M. & Abate-Shen, C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24, 1967–2000 (2010).
Santoni, M. et al. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim. Biophys. Acta - Rev. Cancer 1846, 630–637 (2014).
Hirano, D., Okada, Y., Minei, S., Takimoto, Y. & Nemoto, N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 45, 586–592 (2004).